Senores Pharmaceuticals shares fell over 5% despite strong year-on-year earnings growth, as investors reacted to sequential weakness in EBITDA and margins amid a softer operational performance in the March quarter.
Senores Pharmaceuticals shares fell over 5% despite strong year-on-year earnings growth, as investors reacted to sequential weakness in EBITDA and margins amid a softer operational performance in the March quarter.